Benzinga | Jul 19, 2021 01:19PM EDT

Sanofi's Oral Treatment For Sleeping Sickness Gets FDA Approval

* The FDA has approved Sanofi SA's (NASDAQ:SNY) fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense form of sleeping sickness in patients six years of age and older and weighing at least 20 kg.

* Sleeping sickness is a parasitic disease transmitted by the bite of an infected tse-tse fly.

* Fexinidazole is indicated as a 10-day once-a-day treatment.

* Price Action: SNY shares are down 1.79% at $51.06 during the market session on the last check Monday.

* Related content: Benzinga's Full FDA Calendar.